《中国康复理论与实践》

《中国康复理论与实践》 ›› 2009, Vol. 15 ›› Issue (02): 158-159.

• 临床研究 • 上一篇    下一篇

重组组织型纤溶酶原激活剂联合依达拉奉治疗急性脑梗死疗效观察

吴景芬1,2a;常有军1,2b;吴文斌1,2a;杨友松1,2a;陈祥慧1,2a   

  1. 1. 四川省医学科学院，四川成都市 610072;2. 四川省人民医院a.神经内科;b.康复科，四川成都市 610072
  • 收稿日期:2008-09-18 修回日期:2008-12-02 出版日期:2009-02-01 发布日期:2009-02-01
  • 通讯作者: 常有军

Therapeutic Efficacy of rt-PA Combined with Edaravone on Acute Cerebral Infarction

WU Jing-fen, CHANG You-jun, WU Wen-bin, et al   

  1. The Department of Neurology, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, Chengdu 610072, Sichuan, China
  • Received:2008-09-18 Revised:2008-12-02 Published:2009-02-01 Online:2009-02-01

PDF (PC)

被引次数

7

摘要： 目的 观察重组组织型纤溶酶原激活剂(rt-PA)及rt-PA联合依达拉奉治疗急性脑梗死的临床疗效及安全性。方法 60例符合溶栓条件的急性脑梗死患者分为rt-PA治疗组（予rt-PA治疗）和联合治疗组（予rt-PA联合依达拉奉治疗），各30例，采用欧洲脑卒中临床神经缺损评分标准(ESS)和Barthel指数（BI）评定疗效。结果 联合治疗组治疗后21 d和90 d的ESS积分高于rt-PA治疗组（P＜0.05），90 d时的疗效优于rt-PA治疗组（P＜0.05）。两组患者的不良反应无显著性差异。结论 rt-PA联合依达拉奉治疗急性脑梗死更安全有效，能改善患者的预后。

关键词: 重组组织型纤溶酶原激活剂(rt-PA), 依达拉奉, 急性脑梗死

Abstract: Objective To observe the therapeutic efficacy and safety of recombinant tissue-type plasminogen activator (rt-PA) combined with edaravone on acute cerebral infarction (ACI).Methods 60 cases of ACI were divided into rt-PA group (30 cases, treated by rt-PA only) and trial group (30 cases, treated with rt-PA combined with edaravone). The nerve function deficits of patients in both groups were evaluated by European Stroke Scale (ESS) and Barthel Index (BI) before and after treatment respectively.Results The ESS scores at 21st day and 90th day after treatment in the trial group were significantly higher than those of the patients in the rt-PA group. The effective rate of patients in the trial group was significantly higher than those in the rt-PA group (P＜0.05).Conclusion The treatment of rt-PA combined with edaravone is effective and safe in patients with ACI.

Key words: recombinant tissue-type plasminogen activator (rt-PA), edaravone, acute cerebral infarction